apixaban
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ESRD
Conditions
ESRD, Anticoagulant Toxicity
Trial Timeline
Sep 25, 2016 → Aug 24, 2018
NCT ID
NCT03456648About apixaban
apixaban is a phase 2 stage product being developed by Bristol Myers Squibb for ESRD. The current trial status is completed. This product is registered under clinical trial identifier NCT03456648. Target conditions include ESRD, Anticoagulant Toxicity.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (12)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05187286 | Pre-clinical | Active |
| NCT03594045 | Phase 2 | Terminated |
| NCT02958969 | Approved | Completed |
| NCT03456648 | Phase 2 | Completed |
| NCT02714855 | Pre-clinical | Completed |
| NCT02345343 | Pre-clinical | Completed |
| NCT01885585 | Pre-clinical | Completed |
| NCT02153424 | Pre-clinical | Withdrawn |
| NCT02101112 | Phase 1 | Completed |
| NCT01884350 | Approved | Completed |
| NCT01885598 | Pre-clinical | Completed |
| NCT00252005 | Phase 2 | Completed |
Competing Products
17 competing products in ESRD
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roxadustat | AstraZeneca | Phase 3 | 77 |
| Doravirine | Merck | Approved | 85 |
| MK-2060 + Placebo | Merck | Phase 1 | 33 |
| Induction therapy + Corticosteroids + EVR+rCNI + MPA+sCNI | Novartis | Approved | 85 |
| Mycophenolic Acid (Myfortic) | Novartis | Approved | 85 |
| Avacopan | Amgen | Phase 1 | 32 |
| [¹⁴C]Etelcalcetide | Amgen | Phase 1 | 32 |
| ISIS 416858 + Placebo | Bayer | Phase 2 | 49 |
| ISIS 416858 + Placebo | Bayer | Phase 2 | 49 |
| 10 GE Xenokidney | United Therapeutics | Phase 1/2 | 38 |
| GGTA1 KO Thymokidney | United Therapeutics | Phase 1/2 | 38 |
| Dianeal + Physioneal + Extraneal + Nutrineal | Baxter | Phase 3 | 74 |
| Physioneal + Dianeal + Extraneal + Nutrineal | Baxter | Approved | 82 |
| Dianeal + Dianeal, Extraneal, Nutrineal | Baxter | Phase 3 | 74 |
| Acellular Tissue Engineered Vessel (ATEV) | Humacyte | Phase 3 | 69 |
| Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate + Soluble Ferric Pyrophosphate | Rockwell Medical | Phase 2 | 44 |
| soluble ferric pyrophosphate (SFP) | Rockwell Medical | Pre-clinical | 15 |